Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

NEW YORK -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 9,285,511 common shares, without par value, at a public offering price of $7.00 per common share, and, to certain investors, pre-funded warrants to purchase 1,428,775 common shares at a price of $6.999 per pre-funded warrant, which represents the per share public offering price for the common shares less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to MindMed from the offering, before deducting underwriting discounts, commissions, and other offering-related expenses, are expected to be approximately $75 million. Read More

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering